ClinicalTrials.gg
RecruitingNCT06774963LNCB74-01Updated Oct 29, 2026

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

A Phase 1 interventional study of LNCB74 in Ovarian Cancer, Breast Cancer and Endometrial Cancer, sponsored by LigaChem Biosciences, Inc.. Recruiting at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by LigaChem Biosciences, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.
Updated Oct 29, 2026Site recruiting status changedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
145
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,780 studies in Ovarian Neoplasms with a site in United States — 277 open to participants now, 453 under way, 46 of them phase 3. Ovarian Neoplasms · United States.

Planned enrollment
335th of 1,499
145 · median 47
Started
2025
with 76 others
Phase 1
548 of 1,780
74 open now
Primary completion
2027-12
later than 267 of 451 live
Registered
1,657th of 1,780
by date

Among the 1,780 studies in Ovarian Neoplasms with a site in United States, this one is the 335th largest by planned enrollment of the 1,499 interventional ones that give a count, is one of 77 that started in 2025, is one of 548 in phase 1, reaches primary completion later than 267 of the 451 other live ones, and was the 1,657th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

277 of the 1,780 studies in Ovarian Neoplasms with a site in United States are open now. Recruiting first, the newest first:

272 more — sign in →

All 277 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,780 studies in Ovarian Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.

03

Conditions studied

  • Ovarian Cancer
  • Breast Cancer
  • Endometrial Cancer
  • Non-Small Cell Lung Cancer
  • Advanced or Metastatic Solid Tumors

Keywords

  • Adenoid Cystic Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant provides written
  2. ≥ 18 years of age on day of signing informed consent.
  3. Participant with or cytologically confirmed diagnosis of advanced unresectable and/or solid tumors
  4. A male participant must agree to use and refrain from sperm donation or expecting to father a child
  5. A female participant is eligible to participate if she is not pregnant, not breastfeeding, not a woman of
  6. Have per 1.1 as assessed by the local site investigator/radiology
  7. Able to provide tumor tissue sample.
  8. Willing to undergo fresh tumor at Screening and On-treatment if archival tissue not available
  9. Have an (ECOG) performance status of 0 to 1
  10. greater than or equal to 12 weeks as judged by the Investigator.
  11. Have adequate organ function

Exclusion criteria

Exclusion Criteria:

  1. A who has a positive serum pregnancy test (within 72 hours) prior to treatment.
  2. Has received prior agents within 4 weeks prior to treatment.
  3. Has received anti-cancer chemotherapy (Immunotherapy (non-antibody-based therapy), retinoid therapy, hormonal therapy within 2 weeks prior to treatment.
  4. Has received antibody-based anti-cancer therapy within 4 weeks prior to treatment.
  5. Has received targeted agents and small molecules within 2 weeks or 5 half-lives, whichever is longer.
  6. Has received prior platinum-based chemotherapy and progressed within 4 weeks of initiating therapy (platinum- disease)
  7. Has received an ADC with MMAE payload.
  8. Has received prior radiotherapy within 2 weeks of start of study treatment for focal radiation or within 4 weeks for wide-field radiotherapy
  9. Has received G-CSF or GM-CSF within 7 days prior to start of study treatment.
  10. Has received a live or within 30 days prior to the first dose of study intervention.
  11. Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior to the first dose of study drug
  12. Has a known additional that is progressing or has required active treatment within the past 3 years
  13. Has known active and/or carcinomatous meningitis
  14. Has severe (≥ Grade 3), known allergy or reaction LNCB74 or any of its .
  15. Has a history of (non-infectious) pneumonitis / interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease.
  16. Has active ≥Grade 2 sensory or motor neuropathy.
  17. Has active or chronic corneal disorders, other active ocular conditions requiring ongoing therapy or any corneal disease.
  18. Has an active infection requiring systemic therapy.
  19. Any major surgery within 4 weeks of study drug administration.
  20. Toxicity (except for alopecia) related to prior anti-cancer therapy and/or surgery, unless the toxicity is either resolved, returned to baseline or Grade 1, or deemed irreversible.
  21. Prior organ or tissue allograft.
  22. Uncontrolled or significant cardiovascular disease
  23. Participants with serious or uncontrolled medical disorders.
  24. Participants who are on total parenteral nutrition (TPN)
  25. Participants with history of bowel obstruction within one month of screening
  26. Participants with history of significant ascites requiring paracentesis within 2 weeks of screening
  27. Has a known history of (HIV) infection with an acquired immune deficiency syndrome (AIDS)-defining opportunistic infection within the last year, or a current \<350 cells/µl
  28. Has known active (defined as HBsAg reactive) or known active virus (defined as HCV RNA [qualitative] is detected) infection
  29. Has a history or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participant's participation for the full duration of the study
  30. Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
145 participants (estimated)

Study arms

  • Experimental
    Part 1 - Dose Escalation and Backfills

    Aim: Doses of LNCB74 will be escalated to determine the maximum tolerated dose (MTD), maximum administered dose (MAD) and/or recommended Phase 2 dose (RP2D). One or more dose levels will be backfilled for safety and additional biomarker data.

    Drug: LNCB74

  • Experimental
    Part 2 - Dose Expansion / Optimization

    Aim: The objectives of the Part 2 Dose Expansion/Optimization are: i) to evaluate safety, tolerability, anti-tumor activity, and pharmacodynamics of LNCB74 in a more homogenous population and ii) characterize the minimally safe and effective dose in a particular tumor type and determine recommended Phase 2 dose(s) (RP2D).

    Drug: LNCB74

Interventions

  • DrugLNCB74

    LNCB74 is an antibody drug conjugate being evaluated as a potential treatment for participants with advanced solid tumors. Participants will receive LNCB74 into the vein (IV; intravenously) in 21-day dosing cycles. Participants will continue treatment in the absence of unacceptable toxicities and unequivocal disease progression.

06

What researchers measure

Primary outcomes

  1. Evaluate the safety and tolerability of LNCB74

    Incidence of AEs, SAEs, AEs meeting protocol defined DLT criteria, AEs leading to discontinuation and death, and laboratory abnormalities per NCI CTCAE v5.0

    Time frame: 24 months

  2. Define a recommended Phase 2 dose (RP2D) of LNCB74

    Maximum tolerated dose (MTD), maximum administered dose (MAD) and/or recommended Phase 2 dose (RP2D) of LNCB74

    Time frame: Up to 24 months

Secondary outcomes

  1. Characterize the immunogenicity of LNCB74

    Incidence of anti-drug antibodies to LNCB74

    Time frame: 24 months

  2. Objective Response Rate (ORR)

    Objective Response Rate (ORR) per RECIST v1.1

    Time frame: 24 months

  3. Duration of Response (DOR)

    Duration of response per RECIST v1.1

    Time frame: 24 months

  4. Disease Control Rate (DCR)

    Disease control rate per RECIST v1.1

    Time frame: 24 months

  5. Progression Free Survival Rate (PFSR)

    Progression Free Survival Rate per RECIST v1.1

    Time frame: 6 months

  6. Correlate B7-H4 Expression with Objective Response Rate (ORR)

    To determine B7-H4 expression by immunohistochemistry in a central lab and correlate B7-H4 expression with Objective Response Rate (ORR)

    Time frame: 24 months

  7. Correlate B7-H4 Expression with Duration of Response (DOR)

    To determine B7-H4 expression by immunohistochemistry in a central lab and correlate B7-H4 expression with Duration of Response (DOR)

    Time frame: 24 months

  8. Correlate B7-H4 Expression with Disease Control Rate (DCR)

    To determine B7-H4 expression by immunohistochemistry in a central lab and correlate B7-H4 expression with Disease Control Rate (DCR)

    Time frame: 24 months

  9. Correlate B7-H4 Expression with Progression Free Survival (PFS)

    To determine B7-H4 expression by immunohistochemistry in a central lab and correlate B7-H4 expression with Progression Free Survival (PFS)

    Time frame: 24 months

  10. Progression Free Survival (PFS)

    Progression Free Survival per RECIST v1.1

    Time frame: 24 months

  11. Time to Peak Drug Concentration (Tmax) of LNCB74

    To evaluate the Time to Peak Drug Concentration (Tmax) of LNCB74

    Time frame: Cycle 1 Days 1, 3, 8 and 15; Cycle 3 Days 1, 3, 8 and 15; Day 1 of Cycles 2, 4, 5, 7 and 9

  12. Area Under the Curve (AUC) of LNCB74

    To evaluate the Area Under the Curve (AUC) of LNCB74

    Time frame: Cycle 1 Days 1, 3, 8 and 15; Cycle 3 Days 1, 3, 8 and 15; Day 1 of Cycles 2, 4, 5, 7 and 9

  13. Half-life (T1/2) of LNCB74

    To evaluate the Half-life (T1/2) of LNCB74

    Time frame: Cycle 1 Days 1, 3, 8 and 15; Cycle 3 Days 1, 3, 8 and 15; Day 1 of Cycles 2, 4, 5, 7 and 9

  14. Maximum Serum Concentration (Cmax) of LNCB74

    To evaluate the Maximum Serum Concentration (Cmax) of LNCB74

    Time frame: Cycle 1 Days 1, 3, 8 and 15; Cycle 3 Days 1, 3, 8 and 15; Day 1 of Cycles 2, 4, 5, 7 and 9

07

Study locations

14 of 17 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2027, 35 months after the start.

Of 209 industry-sponsored phase 1 interventional studies under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 35 months is below that.

Counting every sponsor, half of 379 studies reached it within 50 months; a quarter within 32 and three quarters within 76.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Dec 2026 → Dec 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2025
First posted
Jan 14, 2025
StartActual
Jan 7, 2025
Primary completionEst.
Dec 2027was Dec 2026
CompletionEst.
Dec 2027was Dec 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added. Hoag Family Cancer Institute is now Completed
Show 3 added (3 United States)
  • Mount Sinai Tisch Cancer Center · New York, United States
  • Memorial Sloan Kettering Cancer Center · New York, United States
  • Sarah Cannon Research Institute · Nashville, United States
Oct 29, 2026
Primary completion
Dec 2026→Dec 2027
Oct 29, 2026
Study completion
Dec 2026→Dec 2027
Oct 29, 2026
Contact
Study contact now listed: added c•••@ligachembio.com · •••7776. See the current contact
Oct 29, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Hoag Family Cancer Institute · Newport Beach, United StatesContact removed H•••@hoag.org · •••7110Contact removed (no phone or email listed)
Oct 29, 2026
Sponsor
NextCure, Inc.→LigaChem Biosciences, Inc.; Collaborators added: AntibodyChem Biosciences, Inc.; collaborators removed: LigaChem Biosciences, Inc.
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    3 sites added. Hoag Family Cancer Institute is now Completed
    Show 3 added (3 United States)
    • Mount Sinai Tisch Cancer Center · New York, United States
    • Memorial Sloan Kettering Cancer Center · New York, United States
    • Sarah Cannon Research Institute · Nashville, United States
    Primary completion Dec 2026→Dec 2027
    Study completion Dec 2026→Dec 2027
    Sponsor NextCure, Inc.→LigaChem Biosciences, Inc.; Collaborators added: AntibodyChem Biosciences, Inc.; collaborators removed: LigaChem Biosciences, Inc.
    Contact Study contact now listed: added c•••@ligachembio.com · •••7776. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Hoag Family Cancer Institute · Newport Beach, United StatesContact removed H•••@hoag.org · •••7110Contact removed (no phone or email listed)
    + 4 other changes: identifiers, verification date, conditions and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06774963
Lead sponsor
LigaChem Biosciences, Inc.
Collaborators
AntibodyChem Biosciences, Inc.
Responsible party
Sponsor
First posted
Jan 14, 2025
Start date
Jan 7, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

David Browning
Contact
clinicaltrials@ligachembio.com
615-975-7776
Rodrigo Ruiz-Soto, MD
study director · LigaChem Biosciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion